scPharmaceuticals (SCPH) Scheduled to Post Quarterly Earnings on Wednesday

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) is set to post its quarterly earnings results after the market closes on Wednesday, November 13th. Analysts expect scPharmaceuticals to post earnings of ($0.30) per share for the quarter. Investors interested in registering for the company's conference call can do so using this link.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.44). The firm had revenue of $8.05 million for the quarter, compared to analyst estimates of $8.04 million. scPharmaceuticals had a negative return on equity of 201.84% and a negative net margin of 252.18%. On average, analysts expect scPharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

scPharmaceuticals Stock Performance

Shares of scPharmaceuticals stock traded down $0.02 during midday trading on Thursday, hitting $4.32. The company had a trading volume of 223,659 shares, compared to its average volume of 246,779. The stock has a market cap of $216.13 million, a PE ratio of -2.78 and a beta of 0.15. scPharmaceuticals has a 1-year low of $3.24 and a 1-year high of $6.71. The business's 50 day simple moving average is $4.62 and its two-hundred day simple moving average is $4.51. The company has a debt-to-equity ratio of 4.32, a current ratio of 4.84 and a quick ratio of 3.66.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of scPharmaceuticals in a research report on Monday, August 19th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.